Future perspectives in interstitial lung disease: state of the art.

IF 3.3 4区医学 Q1 Medicine European review for medical and pharmacological sciences Pub Date : 2025-03-01 DOI:10.26355/eurrev_202503_37125

R G Carbone, A Monselise, A-M Russell, F Puppo, V F Tapson

{"title":"Future perspectives in interstitial lung disease: state of the art.","authors":"R G Carbone, A Monselise, A-M Russell, F Puppo, V F Tapson","doi":"10.26355/eurrev_202503_37125","DOIUrl":null,"url":null,"abstract":"The interstitial lung disease (ILD) field is rapidly expanding as new insights highlight novel mechanisms and procedures that influence epidemiology, diagnosis, and treatment. The aim of this review is to report on recent advancements and future perspectives in clinical management and research in ILD, particularly in idiopathic pulmonary fibrosis (IPF), for the most common ILD. Whilst high-resolution computed tomography (HRCT) remains the gold standard for diagnosis, we focus on newer diagnostic techniques, including IPF genome analysis and epigenetics, biomarkers, bronchoscope robotic navigation, and transbronchial lung cryo biopsy for improving diagnostic accuracy. Further, we report IPF associated with pulmonary hypertension Group 3 and scores for defining disease progression. Positron emission tomography/computed tomography, treatment with prostacyclin and antifibrotic drugs, and lung transplantation as potential treatments for end-stage IPF are discussed. Lastly, we discuss contemporary perspectives on interstitial lung abnormalities (ILA), IPF associated with lung cancer, and the use of artificial intelligence (AI) for ILD diagnosis and monitoring.Graphical abstract: https://www.europeanreview.org/wp/wp-content/uploads/123-134.jpg.","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"29 3","pages":"123-134"},"PeriodicalIF":3.3000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European review for medical and pharmacological sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.26355/eurrev_202503_37125","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

The interstitial lung disease (ILD) field is rapidly expanding as new insights highlight novel mechanisms and procedures that influence epidemiology, diagnosis, and treatment. The aim of this review is to report on recent advancements and future perspectives in clinical management and research in ILD, particularly in idiopathic pulmonary fibrosis (IPF), for the most common ILD. Whilst high-resolution computed tomography (HRCT) remains the gold standard for diagnosis, we focus on newer diagnostic techniques, including IPF genome analysis and epigenetics, biomarkers, bronchoscope robotic navigation, and transbronchial lung cryo biopsy for improving diagnostic accuracy. Further, we report IPF associated with pulmonary hypertension Group 3 and scores for defining disease progression. Positron emission tomography/computed tomography, treatment with prostacyclin and antifibrotic drugs, and lung transplantation as potential treatments for end-stage IPF are discussed. Lastly, we discuss contemporary perspectives on interstitial lung abnormalities (ILA), IPF associated with lung cancer, and the use of artificial intelligence (AI) for ILD diagnosis and monitoring.

Graphical abstract: https://www.europeanreview.org/wp/wp-content/uploads/123-134.jpg.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

间质性肺疾病的未来展望：最新进展

随着影响流行病学、诊断和治疗的新机制和程序的新见解，间质性肺疾病（ILD）领域正在迅速扩大。本综述的目的是报告ILD的临床管理和研究的最新进展和未来展望，特别是在最常见的ILD的特发性肺纤维化（IPF）方面。虽然高分辨率计算机断层扫描（HRCT）仍然是诊断的金标准，但我们专注于更新的诊断技术，包括IPF基因组分析和表观遗传学，生物标志物，支气管镜机器人导航和经支气管肺冷冻活检，以提高诊断准确性。此外，我们报告了IPF与肺动脉高压第3组相关，以及用于确定疾病进展的评分。讨论了正电子发射断层扫描/计算机断层扫描、前列环素和抗纤维化药物治疗以及肺移植作为终末期IPF的潜在治疗方法。最后，我们讨论了对间质性肺异常（ILA）、与肺癌相关的IPF以及人工智能（AI）在ILD诊断和监测中的应用的当代观点。图形摘要：https://www.europeanreview.org/wp/wp-content/uploads/123-134.jpg。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

European review for medical and pharmacological sciences 医学-药学

CiteScore

5.30

自引率

6.10%

发文量

906

审稿时长

2-4 weeks

期刊介绍： European Review for Medical and Pharmacological Sciences, a fortnightly journal, acts as an information exchange tool on several aspects of medical and pharmacological sciences. It publishes reviews, original articles, and results from original research. The purposes of the Journal are to encourage interdisciplinary discussions and to contribute to the advancement of medicine. European Review for Medical and Pharmacological Sciences includes: -Editorials- Reviews- Original articles- Trials- Brief communications- Case reports (only if of particular interest and accompanied by a short review)